Writing Group Disclosures

Writing group member	Employment	Research grant	Other research support	Speakers’ bureau/honoraria	Expert witness	Ownership interest	Consultant/advisory board	Other
Brian Olshansky	University of Iowa Hospital & Clinic	None	None	Lundbeck†; Sanofi-Aventis*	None	None	Boehringer Ingelheim*; Lundbeck†; Sanofi Aventis*	None
Michael G. Fradley	University of Pennsylvania	Medtronic (investigator-initiated study)*	None	None	None	None	Abbott*; Takeda*	None
Theresa M. Beckie	University of South Florida College of Nursing/College of Medicine	None	None	None	None	None	None	None
Sherry Ann Brown	Medical College of Wisconsin (MCW)/ Froedtert Hospital in Milwaukee	None	None	None	None	None	None	None
Richard K. Cheng	University of Washington Medical Center	None	None	None	None	None	None	None
Susan F. Dent	Duke Cancer Institute	Novartis*	None	None	None	None	Novartis*	None
Anju Nohria	Brigham and Women’s Hospital	Amgen†	None	None	None	None	Takeda Oncology*; AstraZeneca*; Boehringer Ingelheim*	None
Kristen K. Patton	University of Washington	None	None	None	None	None	None	None
Jagmeet P. Singh	Massachusetts General Hospital, Harvard Medical School	None	None	None	None	None	Abbott*; Biotronik*; Boston Scientific*; Cardiologs*; EBR†; Impulse Dynamics*; Medtronic*; Microport (unpaid)*; Sanofi*; Toray*	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

^*

Modest.

^†

Significant.